Jump to content

Draft:Halia Therapeutics, Inc.

From Wikipedia, the free encyclopedia
Halia Therapeutics, Inc.
Company typePrivate
IndustryPharmaceutical, Healthcare
Founded2017; 7 years ago (2017)
FounderDavid Bearss, Ph.D., Jared Bearss, John S. K. Kauwe III
Headquarters
Lehi, UT, United States
Key people
David Bearss, Ph.D., President and Chief Executive Officer
Websitehaliatx.com

Halia Therapeutics[1][2] is a privately-owned pharmaceutical company based in Lehi, Utah that focuses on treating inflammatory disorders by targeting inflammasome.[2]

History

[edit]

Halia Therapeutics was founded in 2017[3] by David Bearss, Ph.D.,[4] Jared Bearss, and Brigham Young University-Hawaii's 11th president John S. K. Kauwe III. The company focuses on therapies for inflammatory disorders and neurological diseases.[5] David Bearss, Ph.D. serves as President and CEO of the company. In 2024, Halia Therapeutics won the Medical & Health Med Tech Award Utah Business Innovation award, and its CEO David Bearss was awarded the Governor’s Medal for Science and Technology the same year, for his involvement as a consultant to the Governor during the COVID-19 pandemic, serving on several boards within the state of Utah, and his involvement in establishing the research arm of the Huntsman Cancer Institute and the U2TAH Therapeutics Accelerator at the University of Utah. [6] [7]

Financing

[edit]

Halia Therapeutics completed Series C funding raised $30M.[8] Financing was led by Todd Pedersen, with continued funding from previous investors. [9] [10]

Indications and Programs

[edit]

Inflammation has been linked to myriad medical conditions[11][12]. Halia Therapeutics' products target inflammation-related indications, including neurological disorders and cancers.[13]

Halia Therapeutics’ lead candidate, HT-6184, inhibits the inflammasome by blocking the interaction between NLRP3 and NEK7[14]. HT-6184 has been shown to be well tolerated in Phase I study in healthy volunteer subjects[15]. HT-6184 is currently being tested in Phase II trials for MDS and inflammatory pain.[16][17] It additionally will be tested in a different formulation that can cross the blood-brain barrier, HT-6153, to treat inflammatory diseases of the eye.[18]

Further therapies that inhibit inflammasome include HT-6258 which will be tested as a treatment for gastroenterology.[18]

Halia Therapeutics’ additional programs that target the inflammasome include HT-6283 for Neuroinflammation, HT-6515 for Dermatology, and HT-6153 for Intervertebral Disk Disease.

Halia Therapeutics has also developed LRRK2 inhibitor that is currently being evaluated in two additional programs. These include, HT-4253, which will be tested to treat Alzheimer’s Disease, and HT-4403 for Parkinson’s Disease.[18][17][19]

Sources

[edit]

References:

  1. ^ "TradeandIndustrydev.com - UT: Halia Therapeutics Opens New HQ and Lab Facilities in Lehi, with Potential for Dozens of Jobs".
  2. ^ a b "ContractPharma.com - Halia Therapeutics Opens New HQ in Lehi, UT".
  3. ^ "UtahBusiness.com - How David J. Bearss co-founded Halia Therapeutics - 7 December 2023". 7 December 2023.
  4. ^ "Biosphere Magazine 2023, page 22" (PDF).
  5. ^ "Deseret News - BYU-led team finds possible protection against Alzheimer's disease - 2 December 2017". 3 December 2017.
  6. ^ "UtahBusiness.com - Introducing the 2023 Innovation Awards honorees, 30 October 2023". 30 October 2023.
  7. ^ "business.utah.gov - Recipients of the 2023 Utah Governor's Science Medals Announced, 31 March 2023". 31 March 2023.
  8. ^ "ENDPOINTS News - Halia's $30M Series C; Windtree assesses 'strategic' options; LifeArc, Gates invest in Africa accelerator, 31 January 2024".
  9. ^ "PR Newswire - Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics, 31 January 2024" (Press release).
  10. ^ "CFO Dive - Biotech CFOs sharpen financing tactics for lean times, 17 January 2023".
  11. ^ "Cleveland Clinic, Inflammation".
  12. ^ Furman, David; Campisi, Judith; Verdin, Eric; Carrera-Bastos, Pedro; Targ, Sasha; Franceschi, Claudio; Ferrucci, Luigi; Gilroy, Derek W.; Fasano, Alessio; Miller, Gary W.; Miller, Andrew H.; Mantovani, Alberto; Weyand, Cornelia M.; Barzilai, Nir; Goronzy, Jorg J.; Rando, Thomas A.; Effros, Rita B.; Lucia, Alejandro; Kleinstreuer, Nicole; Slavich, George M. (December 2019). "Nature.com - Chronic inflammation in the etiology of disease across the life span, 05 December 2019". Nature Medicine. 25 (12): 1822–1832. doi:10.1038/s41591-019-0675-0. PMC 7147972. PMID 31806905.
  13. ^ "Bioworld.com, Halia closes a $30M series C to develop inflammasome inhibitors, 31 January 2024".
  14. ^ Bearss, Benjamin; Bursey, Devan; Avei, Taylor; Mollard, Alexis; Bearss, Jared; Janat-Amsbury, Margit Maria; Bearss, David J. (2 November 2023). "Science Direct, HT-6184 Inhibits the Formation of the NLRP3 Inflammasome in Human Monocytic THP-1 Cells, 2 November 2023". Blood. 65th ASH Annual Meeting Abstracts. 142: 3916. doi:10.1182/blood-2023-182060.
  15. ^ "National Library of Medicine - clinicaltrials.gov, Study to Evaluate HT-6184 in Healthy Subjects, 28 August 2023".
  16. ^ "ashpublications.org, The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML, 28 November 2023".
  17. ^ a b "Pharmaceutical Technology, Halia plans two trials testing its anti-inflammatory lead candidate, 22 August 2023". 22 August 2023.
  18. ^ a b c "BioTuesdays.com - Halia targeting chronic inflammation to keep people healthier, living longer, 22 August 2023". 22 August 2023.
  19. ^ "UtahBusiness.com - Here's how Halia Therapeutics aims to curb Alzheimer's—and more, 20 May 2022". 20 May 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Halia_Therapeutics,_Inc.&oldid=1256160312"